



US009410184B2

(12) **United States Patent  
Sode**(10) **Patent No.: US 9,410,184 B2**  
(45) **Date of Patent: Aug. 9, 2016**(54) **GLUCOSE DEHYDROGENASE**(56) **References Cited**(71) Applicants: **ARKRAY, Inc.**, Kyoto (JP); **Ultizyme  
International Ltd.**, Tokyo (JP)

## FOREIGN PATENT DOCUMENTS

(72) Inventor: **Koji Sode**, Tokyo (JP)

JP	2001-346587	A	12/2001
WO	00/66744	A1	11/2000
WO	2004/005499	A1	1/2004
WO	2006/109578	A1	10/2006

(73) Assignees: **ARKRAY, Inc.**, Kyoto (JP); **Ultizyme  
International Ltd.**, Tokyo (JP)

## OTHER PUBLICATIONS

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 44 days.

International Search Report dated Aug. 12, 2008 issued in the international application No. PCT/JP2008/001624.

(21) Appl. No.: **14/520,807**

International Preliminary Report on Patentability dated Jan. 12, 2010 issued in the international application No. PCT/JP2008/001624.

(22) Filed: **Oct. 22, 2014**Cleton-Jansen et al., "Cloning, characterization and DNA sequencing of the gene encoding the Mr 50000 quinoprotein glucose dehydrogenase from *Acinetobacter calcoaceticus*", *Mol. Gen. Genet.*, 1989, vol. 217, pp. 430-436.(65) **Prior Publication Data**

US 2015/0044711 A1 Feb. 12, 2015

Oubrie et al., "The 1,7 Å crystal structure of the Apo Form of the Soluble Quinoprotein Glucose Dehydrogenase from *Acinetobacter calcoaceticus* reveals a novel internal conserved sequence repeat", *J. Mol. Biol.*, 1999, vol. 289, pp. 319-333, and erratum.**Related U.S. Application Data**

(62) Division of application No. 13/660,316, filed on Oct. 25, 2012, now Pat. No. 8,900,844, which is a division of application No. 12/665,656, filed as application No. PCT/JP2008/001624 on Jun. 23, 2008, now Pat. No. 8,329,439.

Oubrie et al., "Structure and mechanism of soluble quinoprotein glucose dehydrogenase", *The EMBO Journal*, 1999, vol. 18, No. 19, pp. 5187-5194.Oubrie et al., "Active-site structure of the soluble quinoprotein glucose dehydrogenase complexed with methylhydrazine: A covalent cofactor-inhibitor complex", *PNAS*, Oct. 12, 1999, vol. 96, No. 21, pp. 11787-11791.**Foreign Application Priority Data**

(30) Jun. 21, 2007 (JP) ..... 2007-163858

Yagi, et al., "In silico panning for a non-competitive peptide inhibitor, *BMC Bioinformatics*", 2007, vol. 8, p. 11.

UniPro Accession No. A9EP27, created on Feb. 5, 2000.

(51) **Int. Cl.**

<b>C12N 9/02</b>	(2006.01)
<b>C12Q 1/54</b>	(2006.01)
<b>C12Q 1/26</b>	(2006.01)
<b>C07H 21/04</b>	(2006.01)
<b>C12N 9/04</b>	(2006.01)
<b>C12Q 1/00</b>	(2006.01)

*Primary Examiner* — Iqbal H Chowdhury(74) *Attorney, Agent, or Firm* — Morgan, Lewis & Bockius LLP(52) **U.S. Cl.**CPC ..... **C12Q 1/54** (2013.01); **C12N 9/0006** (2013.01); **C12Q 1/006** (2013.01); **C12Y 101/05002** (2013.01)**ABSTRACT**(58) **Field of Classification Search**

None

See application file for complete search history.

(57)

A modified pyrroloquinoline quinone glucose dehydrogenase that exhibits a high selectivity for glucose is provided. A modified pyrroloquinoline quinone glucose dehydrogenase is disclosed in which the amino acid residue G at Position 99 of a pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 1, or the amino acid residue G at Position 100 of the pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 3, is substituted by the amino acid sequence TGZN (where Z is SX, S, or N and X is any amino acid residue). The modified PQQGDH of the present invention may additionally comprise one or more mutations selected from the group consisting of Q192G, Q192A, or Q192S; L193X; E277X; A318X; Y367A, Y367F, or Y367W; G451C; and N452X (where X is any amino acid residue).

**6 Claims, 1 Drawing Sheet**